Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-002 pembrolizumab versus chemotherapy in ipilimumab-refractory advanced melanoma
NL-OMON45068Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2013
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in melanoma (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Feb 2013; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON45068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45068.